Neurobo Pharmaceuticals Stock Alpha and Beta Analysis
| NRBO Stock | USD 3.12 0.25 7.42% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Neurobo Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Neurobo Pharmaceuticals over a specified time horizon. Remember, high Neurobo Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Neurobo Pharmaceuticals' market risk premium analysis include:
Beta 3.16 | Alpha 0.13 | Risk 10.22 | Sharpe Ratio 0.0424 | Expected Return 0.43 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Neurobo |
Neurobo Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Neurobo Pharmaceuticals market risk premium is the additional return an investor will receive from holding Neurobo Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Neurobo Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Neurobo Pharmaceuticals' performance over market.| α | 0.13 | β | 3.16 |
Neurobo Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Neurobo Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Neurobo Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Neurobo Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Neurobo Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Neurobo Pharmaceuticals shares will generate the highest return on investment. By understating and applying Neurobo Pharmaceuticals stock market price indicators, traders can identify Neurobo Pharmaceuticals position entry and exit signals to maximize returns.
Neurobo Pharmaceuticals Return and Market Media
The median price of Neurobo Pharmaceuticals for the period between Wed, Jan 24, 2024 and Tue, Apr 23, 2024 is 4.39 with a coefficient of variation of 20.39. The daily time series for the period is distributed with a sample standard deviation of 0.9, arithmetic mean of 4.41, and mean deviation of 0.75. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Why Obesity-Drug Maker NeuroBo Stock Is Trading Higher | 02/01/2024 |
2 | The Top 3 Stocks to Watch This Week - InvestorPlace | 02/05/2024 |
3 | NeuroBo Pharmaceuticals Signals Updates in Corporate Outlook - TipRanks.com - TipRanks | 02/14/2024 |
4 | Acquisition by Marshall Woodworth of 33496 shares of Neurobo Pharmaceuticals subject to Rule 16b-3 | 03/01/2024 |
5 | Acquisition by Strickland D Gordon of 20000 shares of Neurobo Pharmaceuticals subject to Rule 16b-3 | 03/05/2024 |
6 | NeuroBos Phase 2a trial of DA-124 proceeds after safety review | 03/13/2024 |
7 | Acquisition by Kim Hyung Heon of 20000 shares of Neurobo Pharmaceuticals subject to Rule 16b-3 | 03/15/2024 |
8 | Acquisition by Jeong Tae Heum of 60000 shares of Neurobo Pharmaceuticals at 8. subject to Rule 16b-3 | 03/25/2024 |
9 | NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH | 04/01/2024 |
10 | NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity | 04/17/2024 |
About Neurobo Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Neurobo or other stocks. Alpha measures the amount that position in Neurobo Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Interest Debt Per Share | 0.04 | 0.038 | Revenue Per Share | 0.001242 | 0.001104 |
Neurobo Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Neurobo Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neurobo Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Neurobo Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Neurobo Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Neurobo Pharmaceuticals' management manipulating its earnings.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Neurobo Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Neurobo Pharmaceuticals Backtesting, Neurobo Pharmaceuticals Valuation, Neurobo Pharmaceuticals Correlation, Neurobo Pharmaceuticals Hype Analysis, Neurobo Pharmaceuticals Volatility, Neurobo Pharmaceuticals History and analyze Neurobo Pharmaceuticals Performance. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.Note that the Neurobo Pharmaceuticals information on this page should be used as a complementary analysis to other Neurobo Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Neurobo Stock analysis
When running Neurobo Pharmaceuticals' price analysis, check to measure Neurobo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurobo Pharmaceuticals is operating at the current time. Most of Neurobo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neurobo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurobo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neurobo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Neurobo Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.